Helicobacter pylori enzymes

Helicobacter pylori enzymes constitute a heterogeneous group of proteins with critical roles in bacterial survival, colonization, virulence, and disease progression in the human gastric mucosa[1][3][6]. Key enzymes include urease, which enables survival in the acidic environment by hydrolyzing urea to ammonia and bicarbonate, thereby raising local pH and facilitating colonization[1][3][4][8]. Catalase and superoxide dismutase detoxify reactive oxygen species, protecting the bacteria from host immune responses[1][6]. Alcohol dehydrogenase produces toxic acetaldehyde, phospholipases and proteases damage host epithelial cells[1][3]. Other important enzymes are carbonic anhydrase (acid acclimation, biofilm stability[2]), type II restriction endonucleases (genetic diversity, typing[5]), and various metabolic and biosynthetic enzymes supporting energy production, cell growth, and adaptive resistance[1][4][2]. Many of these enzymes are considered direct or indirect therapeutic targets, with drugs and research interventions aimed at inhibiting key enzymatic functions to treat H. pylori-associated gastritis, ulcer disease, and gastric cancer. However, the correct therapeutic target designation should specify the individual enzyme of interest (e.g., "Helicobacter pylori urease") rather than a general class.

Other names

*H. pylori enzymes**H. pylori enzymatic proteins*Individual enzyme names (e.g., urease, catalase, alcohol dehydrogenase, phospholipase, protease, carbonic anhydrase, glutamine synthetase, etc.)

Enzyme inhibition: Block active sites to prevent substrate conversion (e.g., urease, carbonic anhydrase inhibitors stop ammonia production, acid acclimation); ROS modulation: Target catalase/superoxide dismutase to increase bacterial susceptibility to oxidative stress; Biofilm disruption: Inhibit enzymes (e.g., carbonic anhydrase) involved in biofilm formation to weaken bacterial defense